VR Logo

Mersana Therapeutics Inc. (MRSN) download report


Healthcare | Biotechnology & Pharma Research

Mersana Therapeutics Inc. (MRSN) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need.

IPO Date: 28-Jun-2017

Pres, CEO & Director: Ms. Anna Protopapas M.B.A.

Sr. VP & CFO: Mr. Brian C. DeSchuytner

Listing: NASDAQ: MRSN

Country: United States

Headquarters: Cambridge, MA

Website: https://www.mersana.com

Key Facts

Market cap: $484.96 Mln

Revenue (TTM): $2.07 Mln

Earnings (TTM): $-182.63 Mln

Cash: $230.06 Mln

Total Debt: $37.67 Mln

Insider's Holding: 1.13%

Liquidity: Low

52 Week range: $2.68 - 14.80

Shares outstanding: 96,991,296

7 Years Aggregate:

  • CFO: $-358.37 Mln
  • EBITDA: $-411.33 Mln
  • Net Profit: $-419.41 Mln

Stock Performance

Time Period Mersana Therapeutics (MRSN) S&P BSE Sensex S&P Small-Cap 600
YTD-19.61-9.49-17.79
1 month48.81-2.87-2.72
3 months24.07-8.59-12.17
1 Year-64.130.81-15.82
3 Years6.4910.397.14
5 Years--11.116.20
10 Years--12.0010.33
As on 24-Jun-2022
Year Mersana Therapeutics (MRSN) S&P Small-Cap 600 S&P BSE Sensex
2021-76.6325.2721.99
2020364.409.5715.75
201940.4420.8614.38
2018-74.98-9.705.87